Matthew T. Chang

Active 2014–2023

38
Papers
18,566
Citations
34
h-index
38
i10-index

Citations

Citations per year for Matthew T. Chang1992: 2 citations1998: 1 citations2000: 1 citations2004: 4 citations2005: 1 citations2007: 2 citations2009: 1 citations2013: 2 citations2014: 1 citations2015: 10 citations2016: 65 citations2017: 206 citations2018: 431 citations2019: 1,180 citations2020: 1,457 citations2021: 1,394 citations2022: 1,072 citations2023: 789 citations2024: 1,168 citations2025: 527 citations2026: 24 citations1993–1997: no citations, so these years are not shown1999: no citations, so this year is not shown2001–2003: no citations, so these years are not shown2006: no citations, so this year is not shown2008: no citations, so this year is not shown2010–2012: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,796 citing papers, 30.6% of this breakdownChina: 1,289 citing papers, 10.4% of this breakdownUnited Kingdom: 825 citing papers, 6.7% of this breakdownGermany: 613 citing papers, 4.9% of this breakdownItaly: 590 citing papers, 4.8% of this breakdownCanada: 508 citing papers, 4.1% of this breakdownFrance: 430 citing papers, 3.5% of this breakdownSpain: 391 citing papers, 3.2% of this breakdownJapan: 361 citing papers, 2.9% of this breakdownAustralia: 333 citing papers, 2.7% of this breakdownNetherlands: 312 citing papers, 2.5% of this breakdownSwitzerland: 300 citing papers, 2.4% of this breakdown
0%30.6%Other 21.3%

Fields

  • Medicine50.7%
  • Biochemistry, Genetics and Molecular Biology45.1%
  • Computer Science1.5%
  • Immunology and Microbiology1.3%
  • Agricultural and Biological Sciences0.3%
  • Chemistry0.3%
  • Other0.8%

Topics

  • Cancer Genomics and Diagnostics9.1%
  • Prostate Cancer Treatment and Research4.3%
  • Lung Cancer Treatments and Mutations3.8%
  • Cancer Immunotherapy and Biomarkers2.7%
  • Ubiquitin and proteasome pathways2.1%
  • Genetic factors in colorectal cancer2.1%
  • Other75.9%

Coauthors

All papers

Open in search
  1. OncoKB: A Precision Oncology Knowledge Base

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Antonio Omuro, Michael A. Postow, Dana E. Rathkopf, Alexander N. Shoushtari, Neerav Shukla, Martin H. Voss, Ederlinda Paraiso, Ahmet Zehir, Michael F. Berger, Barry S. Taylor, Leonard B. Saltz, Gregory J. Riely, Marc Ladanyi, David M. Hyman, José Baselga, Paul Sabbatini, David B. Solit, Nikolaus Schultz - JCO Precision Oncology 2017 cited by 2,698

  2. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laetitia Borsu, Justyna Sadowska, Jacklyn Casanova, Ruben Bacares, Iwona Kiecka, Anna Razumova, Julie B Son, Lisa Stewart, Tessara Baldi, Kerry Mullaney, Hikmat Al‐Ahmadie, Efsevia Vakiani, Adam Abeshouse, Alexander Penson, Philip Jonsson, Niedzica Camacho, Matthew T. Chang, Helen Won, Benjamin Groß, Ritika Kundra, Zachary Heins, Hsiao‐Wei Chen, Sarah Phillips, Hongxin Zhang, Jiaojiao Wang, Angelica Ochoa, Jonathan Wills, Michael Eubank, Stacy B. Thomas, Stuart M. Gardos, Dalicia N. Reales, Jesse Galle, Robert Durany, Roy Cambria, Wassim Abida, Andrea Cercek, Darren R. Feldman, Mrinal M. Gounder, A. Ari Hakimi, James J. Harding, Gopa Iyer, Yelena Y. Janjigian, Emmet Jordan, Ciara M. Kelly, Maeve A. Lowery, Luc G.T. Morris, Antonio Omuro, Nitya Raj, Pedram Razavi, Alexander N. Shoushtari, Neerav Shukla, Tara E. Soumerai, Anna M. Varghese, Rona Yaeger, Jonathan Coleman, Bernard H. Bochner, Gregory J. Riely, Leonard B. Saltz, Howard I. Scher, Paul Sabbatini, Mark E. Robson, David S. Klimstra, Barry S. Taylor, José Baselga, Nikolaus Schultz, David M. Hyman, Maria E. Arcila, David B. Solit, Marc Ladanyi, Michael F. Berger - Nature Medicine 2017 cited by 3,517

  3. The Molecular Taxonomy of Primary Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fadi Brimo, Christopher A. Bristow, Denise Brooks, Bradley M. Broom, Alan H. Bryce, Glenn J. Bubley, Eric Burks, Yaron S.N. Butterfield, M. Button, David Canes, Carlos Gilberto Carlotti, Rebecca Carlsen, Michel Carmel, Peter R. Carroll, Scott L. Carter, Richard W. Cartun, Brett S. Carver, June M. Chan, Matthew T. Chang, Yu Chen, Andrew D. Cherniack, Simone Chevalier, Lynda Chin, Juok Cho, Andy Chu, Eric Chuah, Sudha Chudamani, Kristian Cibulskis, Giovanni Ciriello, Amanda Clarke, Matthew R. Cooperberg, Niall M. Corcoran, Anthony J. Costello, Janet E. Cowan, Daniel Crain, Erin Curley, Kerstin A. David, John A. Demchok, Francesca Demichelis, Noreen Dhalla, Rajiv Dhir, Alexandre A. Doueik, Bettina F. Drake, Heidi Dvinge, Natalya Dyakova, Ina Felau, Martin L. Ferguson, Scott Frazer, Stephen J. Freedland, Yao Fu, Stacey Gabriel, Jianjiong Gao, Johanna Gardner, Julie M. Gastier-Foster, Nils Gehlenborg, Mark Gerken, Mark Gerstein, Gad Getz, Andrew K. Godwin, Anuradha Gopalan, Markus Graefen, Kiley Graim, Thomas Gribbin, Ranabir Guin, Manaswi Gupta, Angela Hadjipanayis, Syed Haider, Lucie Hamel, D. Neil Hayes, David I. Heiman and 212 more - Cell 2015 cited by 3,279

  4. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nikolaus Schultz, Mark E. Robson, Clifford A. Hudis, Edi Brogi, Agnès Viale, Larry Norton, Maura N. Dickler, Michael F. Berger, Christine A. Iacobuzio–Donahue, Sarat Chandarlapaty, Maurizio Scaltriti, Jorge S. Reis‐Filho, David B. Solit, Barry S. Taylor, José Baselga - Cancer Cell 2018 cited by 1,006

  5. Genome doubling shapes the evolution and prognosis of advanced cancers

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Genetics 2018 cited by 692

  6. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , İnanç Birol, Tom Bodenheimer, Jay Bowen, Reanne Bowlby, Christopher A. Bristow, Denise Brooks, Rebecca Carlsen, Colleen M. Cebulla, Matthew T. Chang, Andrew D. Cherniack, Lynda Chin, Juok Cho, Eric Chuah, Sudha Chudamani, Carrie Cibulskis, Kristian Cibulskis, Leslie Cope, Sarah E. Coupland, Ludmila Danilova, Timothy Defreitas, John A. Demchok, Laurence Desjardins, Noreen Dhalla, Bita Esmaeli, Ina Felau, Martin L. Ferguson, Scott Frazer, Stacey Gabriel, Julie M. Gastier‐Foster, Nils Gehlenborg, Mark Gerken, Jeffrey E. Gershenwald, Gad Getz, Ewan A. Gibb, Klaus Griewank, Elizabeth A. Grimm, D. Neil Hayes, Apurva M. Hegde, David I. Heiman, Carmen Helsel, Julian M. Hess, Katherine A. Hoadley, Shital Hobensack, Robert A. Holt, Alan P. Hoyle, Xin Hu, Carolyn M. Hutter, Martine J. Jager, Stuart R. Jefferys, Corbin D. Jones, Steven J.M. Jones, Cyriac Kandoth, Katayoon Kasaian, Jaegil Kim, Patrick K. Kimes, Melanie Kucherlapati, Raju Kucherlapati, Eric S. Lander, Michael S. Lawrence, Alexander J. Lazar, Semin Lee, Kristen Leraas, Tara M. Lichtenberg, Pei Lin, Jia Liu, Wenbin Liu, Laxmi Lolla, Yiling Lu, Lisa Iype, Yussanne Ma and 111 more - Cancer Cell 2017 cited by 919

  7. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zora Modrušan, Richard Zang, Yi‐Chen Chen, Michał Kabza, Musaddeque Ahmed, Jason Li, Matthew T. Chang, Danilo Maddalo, Marie Evangelista, Xin Ye, James J. Crawford, Anwesha Dey - Nature Cancer 2023 cited by 195

  8. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity

    Authors: , , , , , , , , , , , - Nature Biotechnology 2015 cited by 832

  9. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

    Authors: , , , , , , , , , , , , , , , , , , - Nature 2017 cited by 562

  10. Accelerating Discovery of Functional Mutant Alleles in Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Neal Rosen, David B. Solit, David M. Hyman, Barry S. Taylor - Cancer Discovery 2017 cited by 426

  11. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Charles M. Rudin, David M. Hyman, Michael F. Berger, David B. Solit, Marc Ladanyi, Gregory J. Riely - Cancer Discovery 2017 cited by 662

  12. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Science 2019 cited by 295

  13. USP7 small-molecule inhibitors interfere with ubiquitin binding

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christiaan Klijn, Elizabeth Blackwood, Scott E. Martin, William F. Forrest, James A. Ernst, Chudi Ndubaku, Xiaojing Wang, Maureen H. Beresini, Vickie Tsui, Carsten Schwerdtfeger, Robert A. Blake, Jeremy Murray, Till Maurer, Ingrid E. Wertz - Nature 2017 cited by 346

  14. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yoon-Hee Hong, Young Su Noh, Munjeong Choi, Oakpil Han, Małgorzata Nowicka, Shrividhya Srinivasan, Yibing Yan, Tae Won Kim, Shiva Malek - Nature 2021 cited by 135

  15. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance

    Authors: , , , - Nature Reviews Clinical Oncology 2017 cited by 328

  16. AKT Inhibition in Solid Tumors With AKT1 Mutations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , José Baselga, Barry S. Taylor - Journal of Clinical Oncology 2017 cited by 325

  17. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma

    Authors: , , , , , , , , , , , , , - Nature Genetics 2016 cited by 312

  18. Copy number alteration burden predicts prostate cancer relapse

    Authors: , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2014 cited by 387

  19. Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Claudia M. Wever, Nathalie A. Johnson, Yanwen Jiang, Jamie Hirata, Deepak Sampath, Lisa Musick, Christopher R. Flowers, Ingrid E. Wertz - American Journal of Hematology 2023 cited by 26

  20. Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties

    Authors: , , , , , , , , , , , , , , , , , - Cancer Discovery 2018 cited by 148

  21. Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2017 cited by 131

  22. Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways

    Authors: , , , , , , , , , , , , , , , , , - Cancer Discovery 2020 cited by 63

  23. 3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets

    Authors: , , , , , , , , , , - Genome Medicine 2017 cited by 233

  24. The Hippo Pathway as a Driver of Select Human Cancers

    Authors: , , , , - Trends in cancer 2020 cited by 79